GlycoTreat develops glyco-immunotherapy with the mission to develop a cure for all humans and animals suffering from allergies.
Utilizing our unique glycan-mediated immune pathway, we are redirecting the immune system to develop lifelong tolerance towards specific antigens.
GlycoTreat’s scientific co-founder, Prof. Yvette van Kooyk, Molecular Cell Biology and Immunology at Amsterdam UMC, received the Spinoza Prize [the highest scientific award in the Netherlands] for her groundbreaking research.
Company Details
- Employees
- 5
- Founded
- 2022
- Address
- Amersfoort, Nl
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://glycotreat.com
- Keywords
- immunotherapy, glycoimmunology, tolerance, allergy, veterinary, allergic asthma, food allergy.
- HQ
- Amersfoort
Glycotreat Questions
Glycotreat's website is https://glycotreat.com
Glycotreat's LinkedIn profile is https://nl.linkedin.com/company/glycotreat
Glycotreat has
5 employees.
View email and phone details for 5
employees at Glycotreat.
Glycotreat's industry is
Biotechnology Research
Glycotreat's top competitors are
Plan Therapeutics,
Center For Disease Neurogenomics,
Reset Technologies Bv,
Transparent Access,
Dutch Brain Research Registry (Hersenonderzoek.nl),
Vn Karazin Kharkiv National University,
One Extra Zero,
Epione Therapeutics,
Chemistry Department Maynooth,
Avisia Therapeutics.
Glycotreat's categories are Biotechnology Research
Glycotreat's founding year is 2022
